No Data
No Data
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Cantor Fitzgerald Maintains Organogenesis(ORGO.US) With Buy Rating, Maintains Target Price $3.5
Organogenesis Trial Results Show Safety, Efficacy of NuShield for DFUs
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
Express News | Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of Nushield for Diabetic Foot Ulcers